U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C35H42N4O5
Molecular Weight 598.7318
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THRX-195518

SMILES

CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(CN5CCC(CC5)C(O)=O)C=C4

InChI

InChIKey=ZVPVPYWMFMUFEZ-UHFFFAOYSA-N
InChI=1S/C35H42N4O5/c1-37(33(40)28-13-11-26(12-14-28)25-39-19-15-29(16-20-39)34(41)42)23-24-38-21-17-30(18-22-38)44-35(43)36-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,29-30H,15-25H2,1H3,(H,36,43)(H,41,42)

HIDE SMILES / InChI
Molecular Formula C35H42N4O5
Molecular Weight 598.7318
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
139594
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:09:22 GMT 2023
Edited
by admin
on Sat Dec 16 15:09:22 GMT 2023
Record UNII
A6X64T4LZ4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THRX-195518
Common Name English
1-((4-(((2-(4-((((1,1'-BIPHENYL)-2-YLAMINO)CARBONYL)OXY)-1-PIPERIDINYL)ETHYL)METHYLAMINO)CARBONYL)PHENYL)METHYL)-4-PIPERIDINECARBOXYLIC ACID
Systematic Name English
4-PIPERIDINECARBOXYLIC ACID, 1-((4-(((2-(4-((((1,1'-BIPHENYL)-2-YLAMINO)CARBONYL)OXY)-1-PIPERIDINYL)ETHYL)METHYLAMINO)CARBONYL)PHENYL)METHYL)
Systematic Name English
REVEFENACIN METABOLITE M2 (HYDROLYSIS OF THE PRIMARY AMIDE)
Common Name English
Code System Code Type Description
FDA UNII
A6X64T4LZ4
Created by admin on Sat Dec 16 15:09:23 GMT 2023 , Edited by admin on Sat Dec 16 15:09:23 GMT 2023
PRIMARY
CAS
909800-36-8
Created by admin on Sat Dec 16 15:09:23 GMT 2023 , Edited by admin on Sat Dec 16 15:09:23 GMT 2023
PRIMARY
PUBCHEM
57459433
Created by admin on Sat Dec 16 15:09:23 GMT 2023 , Edited by admin on Sat Dec 16 15:09:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID401027776
Created by admin on Sat Dec 16 15:09:23 GMT 2023 , Edited by admin on Sat Dec 16 15:09:23 GMT 2023
PRIMARY
Related Record Type Details
OATP-8
TRANSPORTER -> SUBSTRATE
Coordination with OATP1B3 inhibitors (e.g. rifampicin, cyclosporine, etc.) could lead to an increase in systemic exposure of the active metabolite.
MUSCARINIC ACETYLCHOLINE RECEPTOR M5
TARGET -> INHIBITOR
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
MUSCARINIC ACETYLCHOLINE RECEPTOR M1
TARGET -> INHIBITOR
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
OATP1B1
TRANSPORTER -> SUBSTRATE
Coordination with OATP1B1 inhibitors (e.g. rifampicin, cyclosporine, etc.) could lead to an increase in systemic exposure of the active metabolite.
MUSCARINIC ACETYLCHOLINE RECEPTOR M3
TARGET -> INHIBITOR
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
MUSCARINIC ACETYLCHOLINE RECEPTOR M2
TARGET -> INHIBITOR
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
MUSCARINIC ACETYLCHOLINE RECEPTOR M4
TARGET -> INHIBITOR
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
Related Record Type Details
Structure of REVEFENACIN
PARENT -> METABOLITE ACTIVE
MAJOR
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966